메뉴 건너뛰기




Volumn 25, Issue 2, 2012, Pages 175-183

Targeting mTOR in mantle cell lymphoma: Current and future directions

Author keywords

mantle cell lymphoma; mTOR; mTOR inhibitors; PI3K

Indexed keywords

5 FLUORO 3 PHENYL 2 [1 (9H PURIN 6 YLAMINO)PROPYL] 3H QUINAZOLIN 4 ONE; BENDAMUSTINE; BORTEZOMIB; CISPLATIN; CLADRIBINE; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; GEMCITABINE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANOBINOSTAT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PREDNISONE; PROTEIN; PROTEIN KINASE B; RAPAMYCIN; RIDAFOROLIMUS; RITUXIMAB; S6K1 PROTEIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VINCRISTINE;

EID: 84862200758     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2012.04.008     Document Type: Review
Times cited : (19)

References (48)
  • 2
    • 78650985963 scopus 로고    scopus 로고
    • Mantle cell lymphoma: Biology, pathogenesis, and the molecular basis of treatment in the genomic era
    • P. Perez-Galan, M. Dreyling, and A. Wiestner Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Blood 117 2011 26 38
    • (2011) Blood , vol.117 , pp. 26-38
    • Perez-Galan, P.1    Dreyling, M.2    Wiestner, A.3
  • 3
    • 27244434794 scopus 로고    scopus 로고
    • Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways
    • DOI 10.1200/JCO.2005.05.019
    • V. Fernandez, E. Hartmann, and G. Ott Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways J Clin Oncol 23 2005 6364 6369 (Pubitemid 46218848)
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.26 , pp. 6364-6369
    • Fernandez, V.1    Hartmann, E.2    Ott, G.3    Campo, E.4    Rosenwald, A.5
  • 4
    • 0038299000 scopus 로고    scopus 로고
    • Sirolimus: Its discovery, biological properties, and mechanism of action
    • DOI 10.1016/S0041-1345(03)00211-2
    • S.N. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 2003 7S 14S (Pubitemid 36547910)
    • (2003) Transplantation Proceedings , vol.35 , Issue.SUPPL. 3
    • Sehgal, S.N.1
  • 5
    • 34347220473 scopus 로고    scopus 로고
    • Defining the Role of mTOR in Cancer
    • DOI 10.1016/j.ccr.2007.05.008, PII S1535610807001511
    • D.A. Guertin, and D.M. Sabatini Defining the role of mTOR in cancer Cancer Cell 12 2007 9 22 (Pubitemid 47001784)
    • (2007) Cancer Cell , vol.12 , Issue.1 , pp. 9-22
    • Guertin, D.A.1    Sabatini, D.M.2
  • 6
    • 78650510609 scopus 로고    scopus 로고
    • MTOR: From growth signal integration to cancer, diabetes and ageing
    • Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol; 12: 21-35.
    • Nat Rev Mol Cell Biol , vol.12 , pp. 21-35
    • Zoncu, R.1    Efeyan, A.2    Sabatini, D.M.3
  • 7
    • 13844312400 scopus 로고    scopus 로고
    • Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
    • DOI 10.1126/science.1106148
    • D.D. Sarbassov, D.A. Guertin, S.M. Ali, and D.M. Sabatini Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex Science 307 2005 1098 1101 (Pubitemid 40262113)
    • (2005) Science , vol.307 , Issue.5712 , pp. 1098-1101
    • Sarbassov, D.D.1    Guertin, D.A.2    Ali, S.M.3    Sabatini, D.M.4
  • 8
    • 83255188843 scopus 로고    scopus 로고
    • Regulation, role, and targeting of akt in cancer
    • Davies MA. Regulation, role, and targeting of akt in cancer. J Clin Oncol; 29: 4715-4717.
    • J Clin Oncol , vol.29 , pp. 4715-4717
    • Davies, M.A.1
  • 9
    • 3342895823 scopus 로고    scopus 로고
    • Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
    • DOI 10.1016/j.cub.2004.06.054, PII S0960982204004713
    • D.D. Sarbassov, S.M. Ali, and D.H. Kim Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton Curr Biol 14 2004 1296 1302 (Pubitemid 38991819)
    • (2004) Current Biology , vol.14 , Issue.14 , pp. 1296-1302
    • Dos D. Sarbassov1    Ali, S.M.2    Kim, D.-H.3    Guertin, D.A.4    Latek, R.R.5    Erdjument-Bromage, H.6    Tempst, P.7    Sabatini, D.M.8
  • 10
    • 67651210833 scopus 로고    scopus 로고
    • Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth
    • H.A. Acosta-Jaquez, J.A. Keller, and K.G. Foster Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth Mol Cell Biol 29 2009 4308 4324
    • (2009) Mol Cell Biol , vol.29 , pp. 4308-4324
    • Acosta-Jaquez, H.A.1    Keller, J.A.2    Foster, K.G.3
  • 11
    • 84055178474 scopus 로고    scopus 로고
    • Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
    • B. Magnuson, B. Ekim, and D.C. Fingar Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks Biochem J 441 2012 1 21
    • (2012) Biochem J , vol.441 , pp. 1-21
    • Magnuson, B.1    Ekim, B.2    Fingar, D.C.3
  • 12
    • 33646917622 scopus 로고    scopus 로고
    • Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
    • M. Rivera, J.I. Kreisberg, and M.M. Mita Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor JCO 23 2005 3033
    • (2005) JCO , vol.23 , pp. 3033
    • Rivera, M.1    Kreisberg, J.I.2    Mita, M.M.3
  • 14
    • 77649286736 scopus 로고    scopus 로고
    • Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E
    • A.C. Hsieh, M. Costa, and O. Zollo Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E Cancer Cell 17 2010 249 261
    • (2010) Cancer Cell , vol.17 , pp. 249-261
    • Hsieh, A.C.1    Costa, M.2    Zollo, O.3
  • 15
    • 13444259647 scopus 로고    scopus 로고
    • Regulation of cap-dependent translation by eIF4E inhibitory proteins
    • DOI 10.1038/nature03205
    • J.D. Richter, and N. Sonenberg Regulation of cap-dependent translation by eIF4E inhibitory proteins Nature 433 2005 477 480 (Pubitemid 40204297)
    • (2005) Nature , vol.433 , Issue.7025 , pp. 477-480
    • Richter, J.D.1    Sonenberg, N.2
  • 17
    • 70350114434 scopus 로고    scopus 로고
    • Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine
    • K.V. Inamdar, J.E. Romaguera, and E. Drakos Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine Cancer 115 2009 4727 4736
    • (2009) Cancer , vol.115 , pp. 4727-4736
    • Inamdar, K.V.1    Romaguera, J.E.2    Drakos, E.3
  • 19
    • 77953932867 scopus 로고    scopus 로고
    • Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas
    • A.P. Bhatt, P.M. Bhende, and S.H. Sin Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas Blood 115 2010 4455 4463
    • (2010) Blood , vol.115 , pp. 4455-4463
    • Bhatt, A.P.1    Bhende, P.M.2    Sin, S.H.3
  • 20
    • 61349141302 scopus 로고    scopus 로고
    • Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
    • M.E. Feldman, B. Apsel, and A. Uotila Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol 7 2009 e38
    • (2009) PLoS Biol , vol.7 , pp. 38
    • Feldman, M.E.1    Apsel, B.2    Uotila, A.3
  • 21
    • 0032968603 scopus 로고    scopus 로고
    • Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas
    • DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9
    • M.P. Butler, S.I. Wang, and R.S. Chaganti Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas Genes Chromosomes Cancer 24 1999 322 327 (Pubitemid 29115870)
    • (1999) Genes Chromosomes and Cancer , vol.24 , Issue.4 , pp. 322-327
    • Butler, M.P.1    Wang, S.I.2    Chaganti, R.S.K.3    Parsons, R.4    Dalla-Favera, R.5
  • 23
    • 33748128925 scopus 로고    scopus 로고
    • Inhibition of Akt/mTOR signalling pathway induces cell cycle arrest and apoptosis in mantle cell lymphoma
    • [abstract 2415]
    • E. Peponi, e Drakos, and G. Reyes Inhibition of Akt/mTOR signalling pathway induces cell cycle arrest and apoptosis in mantle cell lymphoma Blood 106 2005 [abstract 2415]
    • (2005) Blood , vol.106
    • Peponi, E.1    Drakos, E.2    Reyes, G.3
  • 27
    • 32044445067 scopus 로고    scopus 로고
    • TORgeting oncogene addiction for cancer therapy
    • DOI 10.1016/j.ccr.2006.01.021, PII S1535610806000316
    • A.Y. Choo, and J. Blenis TORgeting oncogene addiction for cancer therapy Cancer Cell. 9 2006 77 79 (Pubitemid 43202658)
    • (2006) Cancer Cell , vol.9 , Issue.2 , pp. 77-79
    • Choo, A.Y.1    Blenis, J.2
  • 28
    • 34948830177 scopus 로고    scopus 로고
    • Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells
    • DOI 10.1182/blood-2005-11-026344
    • N. Kawamata, J. Chen, and H.P. Koeffler Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood 110 2007 2667 2673 (Pubitemid 47523191)
    • (2007) Blood , vol.110 , Issue.7 , pp. 2667-2673
    • Kawamata, N.1    Chen, J.2    Koeffler, H.P.3
  • 29
    • 51849147986 scopus 로고    scopus 로고
    • GSK-3beta inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma
    • J. Dal Col, and R. Dolcetti GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma Cell Cycle 7 2008 2813 2816
    • (2008) Cell Cycle , vol.7 , pp. 2813-2816
    • Dal Col, J.1    Dolcetti, R.2
  • 31
    • 46749155539 scopus 로고    scopus 로고
    • Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
    • J. Dal Col, P. Zancai, and L. Terrin Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma Blood 111 2008 5142 5151
    • (2008) Blood , vol.111 , pp. 5142-5151
    • Dal Col, J.1    Zancai, P.2    Terrin, L.3
  • 32
    • 34248653084 scopus 로고    scopus 로고
    • Antiproliferative activity of RAD001 as a single-agent and combined with other agents in mantle cell lymphoma
    • [2197abstract]
    • T. Haritunians, A. Mori, and J. O'Kelly Antiproliferative activity of RAD001 as a single-agent and combined with other agents in mantle cell lymphoma Am Assoc Can Res 2006 [2197abstract]
    • (2006) Am Assoc Can Res
    • Haritunians, T.1    Mori, A.2    O'Kelly, J.3
  • 33
    • 34248647440 scopus 로고    scopus 로고
    • Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma
    • DOI 10.2353/ajpath.2006.051078
    • E. Peponi, E. Drakos, and G. Reyes Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma Am J Pathol 169 2006 2171 2180 (Pubitemid 351181976)
    • (2006) American Journal of Pathology , vol.169 , Issue.6 , pp. 2171-2180
    • Peponi, E.1    Drakos, E.2    Reyes, G.3    Leventaki, V.4    Rassidakis, G.Z.5    Medeiros, L.J.6
  • 34
    • 27144455334 scopus 로고    scopus 로고
    • Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells
    • S. Hipp, I. Ringshausen, and M. Oelsner Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells Haematologica 90 2005 1433 1434 (Pubitemid 41503659)
    • (2005) Haematologica , vol.90 , Issue.10 , pp. 1433-1434
    • Hipp, S.1    Ringshausen, I.2    Oelsner, M.3    Bogner, C.4    Peschel, C.5    Decker, T.6
  • 36
    • 84863393353 scopus 로고    scopus 로고
    • Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies
    • M. Gupta, A.E. Wahner Hendrickson, and S.S. Yun Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies Blood 119 2012 476 487
    • (2012) Blood , vol.119 , pp. 476-487
    • Gupta, M.1    Wahner Hendrickson, A.E.2    Yun, S.S.3
  • 37
    • 76749118059 scopus 로고    scopus 로고
    • Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma
    • Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res; 70: 1408-1418.
    • Cancer Res , vol.70 , pp. 1408-1418
    • Fernandez, V.1    Salamero, O.2    Espinet, B.3
  • 40
    • 68949102180 scopus 로고    scopus 로고
    • Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
    • G. Hess, R. Herbrecht, and J. Romaguera Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829
    • (2009) J Clin Oncol , vol.27 , pp. 3822-3829
    • Hess, G.1    Herbrecht, R.2    Romaguera, J.3
  • 41
    • 84862231092 scopus 로고    scopus 로고
    • Effect of prognostic risk classification on temsirolimus efficacy and safety outcomes in patients with relapsed/refractory mantle cell lymphoma
    • G. Hess, L. Kang, and P.J. Moran Effect of prognostic risk classification on temsirolimus efficacy and safety outcomes in patients with relapsed/refractory mantle cell lymphoma Blood 2011 118
    • (2011) Blood , pp. 118
    • Hess, G.1    Kang, L.2    Moran, P.J.3
  • 42
    • 79958840413 scopus 로고    scopus 로고
    • PILLAR-1: Preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib
    • O. O'Connor, L. Popplewell, and J. Winter PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib Blood 2010 116
    • (2010) Blood , pp. 116
    • O'Connor, O.1    Popplewell, L.2    Winter, J.3
  • 43
    • 79960510811 scopus 로고    scopus 로고
    • A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
    • C. Renner, P.L. Zinzani, and R. Gressin A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Blood 2010 116
    • (2010) Blood , pp. 116
    • Renner, C.1    Zinzani, P.L.2    Gressin, R.3
  • 44
    • 79953182631 scopus 로고    scopus 로고
    • Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study
    • S.M. Ansell, H. Tang, and P.J. Kurtin Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study Lancet Oncol 12 2011 361 368
    • (2011) Lancet Oncol , vol.12 , pp. 361-368
    • Ansell, S.M.1    Tang, H.2    Kurtin, P.J.3
  • 46
    • 84867334720 scopus 로고    scopus 로고
    • Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: Report on an ongoing phase I/II trial
    • G. Hess, U. Keller, and J. Atta Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial Blood 2011 118
    • (2011) Blood , pp. 118
    • Hess, G.1    Keller, U.2    Atta, J.3
  • 47
    • 84880890111 scopus 로고    scopus 로고
    • CAL-101 (GS-1101), a specific inhibitor of phosphatidylinositol-3-Kinase- Delta (PI3K), disrupts signals from the microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell lymphoma (MCL)
    • S.A. Meadows, A. Kashishian, and D. Johnson CAL-101 (GS-1101), a specific inhibitor of phosphatidylinositol-3-Kinase-Delta (PI3K), disrupts signals from the microenvironment, induces apoptosis, and enhances the antitumor activity of everolimus (RAD001), an inhibitor of mammalian target of rapamycin (mTOR), in mantle cell lymphoma (MCL) Blood 2011 118
    • (2011) Blood , pp. 118
    • Meadows, S.A.1    Kashishian, A.2    Johnson, D.3
  • 48
    • 84862193169 scopus 로고    scopus 로고
    • Phase i trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies
    • S. Kumar, J.R. Mikhael, and B. Laplant Phase I trial of a novel combination of an HDAC inhibitor (LBH589) and an mTOR inhibitor (RAD001) in lymphoid and plasma cell malignancies Blood 2011 118
    • (2011) Blood , pp. 118
    • Kumar, S.1    Mikhael, J.R.2    Laplant, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.